Sofinnova Partners, a life sciences venture capital firm, has closed its latest fund, Sofinnova Capital XI, at €650 million. The fund will support early-stage biotech and medtech ventures across Europe and North America.
Sofinnova Partners secures €650M to back breakthroughs in biopharma and medical technology
November 17, 2025